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Abstract 
 
Background/Aims: Frail patients with chronic kidney disease (CKD) have an increased 
hospitalisation and mortality rate. However, many popular frailty screening methods have 
not been validated in patients with CKD. This study evaluates the diagnostic accuracy of 
several frailty screening methods in patients with CKD G4-5 and those established on 
haemodialysis (G5D). 
 
Methods: Ninety participants with CKD G4-5D were recruited from Nephrology Outpatient 
Clinics and two Haemodialysis Units between December 2016 and December 2017. Frailty 
was diagnosed using the Fried Frailty Phenotype. The following frailty screening tests were 
evaluated: Clinical Frailty Scale, PRISMA-7, CKD Frailty Index, CKD FI-LAB, walking speed, 
hand grip strength and Short Physical Performance Battery. 
 
Results: The mean age of participants was 69 years (SD ±13). A third of participants were 
dialysis dependent. Nineteen (21%) patients were categorised as frail, 42 (47%) as pre-frail 
and 29 (32%) as robust. Overall, walking speed was the most discriminative measure (AUC 
0.97 [95% confidence interval [CI]: 0.93 to 1.00], sensitivity 0.84 [95% CI: 0.62 to 0.94], 
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specificity 0.96 [95% CI: 0.88 to 0.99]). The Clinical Frailty Scale had the best performance of 
the non-physical assessments (AUC 0.90 [95% CI: 0.84 to 0.97], sensitivity 0.79 [95% CI: 0.57 
to 0.91], specificity 0.87 [95% CI: 0.78 to 0.93]). 
 
Conclusions: Walking speed can be used to accurately screen for frailty in CKD populations. 
If it is not practical to perform a physical assessment to screen for frailty, the Clinical Frailty 
Scale is an accurate alternative. 
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AUC   Area Under the Curve 
CI   Confidence Interval 
CKD   Chronic kidney disease 
CKD G4  Chronic kidney disease stage 4 
CKD G5  Chronic kidney disease stage 5 
CKD G5D  Dialysis-dependent chronic kidney disease 
FI   Frailty Index 
IQR   Interquartile range 
ROC   Receiver Operator Characteristic 
SCREEN I Seniors in the Community: Risk Evaluation for Eating and Nutrition 
Index 
SD   Standard deviation 
SPPB   Short Physical Performance Battery 
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INTRODUCTION 
 
Frailty is an especially problematic condition associated with ageing, though it is not 
universally experienced by all elderly individuals [1]. It is a state of increased vulnerability 
such that individuals who may otherwise live independently require additional care and 
support when exposed to even minor physical stressors, for example a simple infection or 
fall [1]. It is the result of progressive and sustained deterioration of numerous physiological 
processes, which when accumulated are associated with adverse health outcomes [1]. Many 
of the pathophysiological processes inherent to chronic kidney disease (CKD) appear to 
propagate the trajectory from robustness to frailty [2]. The prevalence of frailty increases 
with worsening kidney function, with a report categorising as many as two thirds of dialysis-
dependent CKD patients as frail [3,4]. Importantly, frail patients with CKD have worse 
outcomes than those that are robust with CKD, including an increased falls, hospitalisation 
and mortality rate [3-12]. 
 
An international consensus group has advised that frailty screening should be routinely 
performed in older adults so that targeted management strategies can be offered [13]. 
Arguably, this is especially important in those with chronic conditions, such as CKD, given 
the associated predisposition to frailty. Several concepts of frailty have been proposed with 
varying degrees of physical, psychological and social components. The two most popular 
concepts are the Fried Physical Frailty Phenotype and the deficit accumulation model, also 
known as the Frailty Index (FI) [14,15]. Though both have their individual merits, the Frailty 
Phenotype has a more robust evidence base in terms of predicting outcomes in CKD cohorts 
[3]. The Frailty Phenotype is a time-consuming evaluation involving a combination of 
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questionnaires and physical assessments (Table 1) [14]. It is therefore not practical to 
perform this assessment routinely within nephrology outpatient services. Unfortunately, 
there is poor agreement between nephrologist-perceived frailty and this suggested 
diagnostic criteria for physical frailty [16]. Hence, there is a need for an efficient, sensitive 
and discriminative outpatient screening method in the CKD population that identifies at risk 
individuals likely to have frailty, as defined by an acknowledged operationalised definition of 
the construct of frailty. Several frailty screening methods have been validated in the general 
older population [17]. However, many popular frailty screening methods have not been 
studied in CKD patients. This study evaluates the diagnostic accuracy of several proposed 
frailty screening methods in patients with CKD stage 4 and 5 (G4-5) and those established 
on haemodialysis (G5D), using the Frailty Phenotype as the reference standard. 
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METHODS 
 
Study Design and Participant Selection 
 
A convenience series of participants was recruited from Lancashire Teaching Hospitals NHS 
Foundation Trust between December 2016 and December 2017 from nephrology outpatient 
clinics and two Haemodialysis Units. Though there are distinctions between patients that 
are pre-dialysis and dialysis-dependent, the drivers of frailty are similar and the clinical 
expression of frailty is comparable [18]. Therefore, patients ≥18 years old with CKD G4-5 
and CKD G5D were eligible for participation in the study. Patients who had a lower limb 
amputation, metastatic carcinoma, unstable angina or who had a been diagnosed, in the 
preceding 3 months, with a myocardial infarction, transient ischaemic attack or stroke were 
excluded from the study. Patients who did not have sufficient understanding of the English 
language to complete study questionnaires were also excluded. Ethical approval was 
obtained from the NHS Health Research Authority (IRAS Project ID 216379). Formal written 
informed consent was obtained for all participants. 
 
Data Collection and Analyses 
 
Prior to the assessment of index tests, baseline demographic and clinical characteristics data 
was collected from medical records and during participant interview/assessment. All 
participants had a Charlson Comorbidity Index score calculated and a Karnofsky 
Performance Status Scale assessment performed. Participants also completed the Mini-
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Mental State Examination and the Seniors in the Community: Risk Evaluation for Eating and 
Nutrition Index (SCREEN I) [19,20]. 
 
The following frailty screening methods were assessed: Clinical Frailty Scale, PRISMA-7 
questionnaire, CKD Frailty Index (FI), CKD FI-LAB, walking speed, hand grip strength and the 
Short Physical Performance Battery (SPPB) [15,21-24]. The Clinical Frailty Scale is a frailty 
assessment tool that provides 9 descriptors of levels of fitness/frailty (Figure 1) [15]. It relies 
upon a health professional’s assessment of an individual’s frailty status using the descriptors 
as guidance. A score of ‘4’ defines individuals as ‘vulnerable’, whereas a score of ‘5’ 
considers individuals to be ‘mildly frail’. The Clinical Frailty Scale was assessed by a doctor 
who had access to participant clinical records prior to performing the assessment [15]. The 
British Geriatrics Society has recommended the PRISMA-7 as a frailty screening tool, with a 
cut-off of ≥3 used to identify vulnerable individuals (Table 2) [21,25]. Participants were 
asked the questions within the PRISMA-7 questionnaire by a member of the research team. 
Published recommendations were used to construct a CKD FI and CKD FI-LAB 
(Supplementary Table 1 and 2, respectively) [22,23,26]. Although the FI was not originally 
intended to be dichotomised, a cut-off of >0.21 has been suggested in the literature [26]. At 
least 70% of variables were required to generate a CKD FI-LAB score [23].  
 
Hand grip strength (Takei 5101 GRIP-D dynamometer, Takei Scientific Inst. Co. Ltd., Niigata, 
Japan) was assessed in the seated position with the elbow positioned at 90 degrees, 
supported by the arm of a chair, and the dynamometer supported by the assessor. Both 
arms were examined with the highest score from three efforts from each side being used 
for analysis [27]. The body mass index and gender stratified hand grip strength cut-offs 
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proposed by the Fried Frailty Phenotype were used to identify frailty [14]. Lauretani et al’s 
proposed cut-offs of <30kg for men and <20kg for women for the diagnosis of sarcopenia 
were also assessed [28]. Walking speed was assessed by asking participants to walk 15 feet 
(4.57m) at their normal walking pace on two occasions. Participants were advised to use 
their walking aid, if they normally used one. Infrared timing gates (Brower Timing System 
2012, Brower Timing Systems, Draper, UT, USA) were used to record walking time. The 
fastest of two trials was used for analysis. Participants physically unable to complete the 
assessment were assigned the slowest time within the cohort. The height and gender 
stratified walking speed cut-offs suggested by the Fried Frailty Phenotype were used to 
identify frailty [14]. Lauretani et al’s proposed cut-off of ≤0.8 metres/second for the 
diagnosis of sarcopenia was also assessed [28]. Finally, the SPPB, a composite measure of 
lower extremity function, was performed [24,29]. In addition to an assessment of walking 
speed described above, it includes an assessment of balance and time to complete 5 chair 
stands [24,29]. A cut-off of 9 has been suggested to identify at risk individuals [29]. 
 
The Frailty Phenotype was used as the reference standard for all screening tests [14]. It was 
assessed as originally described by Fried et al, including assessments of unintentional weight 
loss, weakness (handgrip strength), self-perceived exhaustion, slowness (walking speed) and 
physical activity (Table 1) [14]. Frailty was diagnosed if 3 or more frailty criteria were 
present. Pre-frailty was defined as the presence of 1 or 2 frailty criteria. The Frailty 
Phenotype assessment was performed at the same study visit as, and immediately 
following, index test assessments (except in the case of hand grip strength, walking speed 
and SPPB assessments, which were performed concurrently). 
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Given that hand grip strength and walking speed were also components of the Frailty 
Phenotype, a modified version of the Frailty Phenotype was created and used as the 
reference standard in a sensitivity analysis. Participants completed the RAND 36-Item Health 
Survey 1.0 and were assigned 2 points if they scored <75 in the physical function domain. As 
described by Johansen et al, this score replaced the measures of weakness and slowness 
described in the original Frailty Phenotype [4]. Unintentional weight loss, self-perceived 
exhaustion and physical activity were assessed as described by Fried et al (Table 1) [14]. 
 
Statistical Analysis 
 
All statistical analyses were performed on IBM SPSS Statistics Software (version 22, IBM 
Corp) or StatsDirect Statistical Software (version 3.0.167, 28/01/2016). Descriptive statistics 
were used to summarise demographic data and clinical characteristics. Differences in 
baseline demographic and clinical characteristic data between non-frail and frail 
participants was assessed using the Independent T test, Mann Whitney U test, Chi-squared 
test and Fishers Exact test depending upon the type and distribution of the data. 
Considering type 1 errors associated with multiple comparisons, a Holm-Bonferroni 
Sequential Correction was applied when comparing baseline demographics and clinical 
characteristics between groups [30,31]. The Chi-squared test for trend was used to assess 
the differences between the proportion of participants categorised as robust, pre-frail and 
frail by CKD stage. The correlation between index tests and the Frailty Phenotype was 
assessed using Spearman’s Correlation. Receiver Operator Characteristic (ROC) analyses 
were performed for the screening tests to establish the Area Under the Curve (AUC) and 
review the sensitivity and specificity of test cut-offs. Additional tests of diagnostic accuracy 
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included: positive predictive value, negative predictive value, positive likelihood ratio and 
negative likelihood ratio. A two-tailed p value <0.05 was considered statistically significant.  
 
Sample Size 
 
The sample size calculation was primarily based on obtaining a 95% confidence interval 
width of no more than 0.17 for the Spearman correlation between the Clinical Frailty Scale 
and the Frailty Phenotype scores, assuming a true correlation of 0.8. This gave a minimum 
sample size of 90, using the two-stage approximation suggested by Bonnett and Wright [32]. 
A sample size of 90 (with an assumed 20 frail and 70 non-frail individuals, defined by the 
Frailty Phenotype) also enables an estimation of the AUC from a ROC curve analysis to 
within ±0.1 with 95% confidence, assuming a true AUC of 0.9.[33] 
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RESULTS 
 
A total of 90 participants completed all assessments (Figure 2). The mean age of participants 
was 69 years (SD ±13) with an equal number of male and female participants. Most 
participants were white British (n=87, 97%). A third of participants were dialysis dependent. 
Nineteen (21%) patients were categorised as frail, 42 (47%) as pre-frail and 29 (32%) as 
robust. Study visits were approximately 90 minutes in duration. Breaks were allowed as 
needed, though participants did not report suffering any fatigue during visits. No adverse 
events occurred during assessments.  
 
Frailty Associations 
 
Table 3 demonstrates the demographics and clinical characteristics of non-frail (including 
robust and pre-frail) and frail participants. Frail participants had a lower Karnofsky score (60 
vs. 80, p<0.001) than non-frail participants. Notably, there was no statistically significant 
difference in age and Charlson Comorbidity Index between frail and non-frail participants 
(73 years vs. 68 years [p=1.00] and 4 vs. 3 [p=1.00], respectively). There was a higher 
proportion of dialysis-dependent participants categorised as frail when participants were 
sub-classified as robust, pre-frail and frail and by CKD stage (CKD G4 11%, CKD G5 20%, CKD 
G5D 33%, p=0.01, Figure 3).  
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Frailty Screening Methods 
 
Table 4 demonstrates the diagnostic accuracy of the frailty screening methods. Overall, 
walking speed had the highest AUC value (0.97 [95% confidence interval [CI]: 0.93 to 1.00]). 
The Frailty Phenotype walking speed criterion cut-off was most discriminative with a 
sensitivity of 0.84 (95% CI: 0.62 to 0.94) and specificity of 0.96 (95% CI: 0.88 to 0.99). This 
was associated with a high positive predictive value and negative predictive value (0.84 
[95% CI: 0.62 to 0.94] and 0.96 [95% CI: 0.88 to 0.99], respectively). Of the non-physical 
assessments, the Clinical Frailty Scale assessment had the highest AUC value (0.90 [95% CI: 
0.84 to 0.97]). It had good sensitivity and specificity when using a cut-off of ≥5 (0.79 [95% CI: 
0.57 to 0.91] and 0.87 [95% CI: 0.78 to 0.93], respectively). The negative predictive value 
was excellent (0.94 [95% CI: 0.85 to 0.98]). The CKD FI-LAB had the worst performance with 
a low and non-significant AUC value (0.63 [95% CI: 0.50 to 0.78; p=0.08]). Supplementary 
Table 3 demonstrates cross-tabulation of the index test results by Frailty Phenotype frailty 
diagnosis. 
 
Table 5 illustrates the diagnostic accuracy of frailty screening methods in CKD G4-5D 
categorised by age and dialysis-dependency. The frailty screening methods performed 
similarly in these sub-groups. Notable exceptions include the PRISMA-7 that had a non-
significant AUC value in the <65 age group, the CKD FI-LAB that had a higher AUC value in 
the <65 years age group and hand grip strength that had a lower, though still reasonable, 
AUC value in the dialysis-dependent group. 
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Sensitivity Analyses 
 
Using the modified version of the Frailty Phenotype, 47 participants (52%) were categorised 
as frail. When using this as the reference standard, the AUC value, though attenuated, 
remained high for all the physical assessments with walking speed again having the highest 
AUC value (walking speed AUC 0.84 [95% CI: 0.76 to 0.92], hand grip strength AUC 0.77 
[95% CI: 0.67 to 0.86] and SPPB AUC 0.81 [95% CI: 0.71 to 0.90]).  
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DISCUSSION 
 
To our knowledge, although frailty screening methods have been evaluated in CKD 
populations, this is the first study that evaluates the diagnostic accuracy of the Clinical 
Frailty Scale, PRISMA-7 and FI-LAB in a pre-dialysis and dialysis dependent CKD population 
[3,34-37]. Comparable to other reports, the prevalence of frailty increased with worsening 
kidney function in this cohort [5,38,39]. There was a similar age between non-frail and frail 
groups, highlighting that frailty is a syndrome that is not merely due to the ageing process. 
In addition, there was no statistically significant difference in the Charlson Comorbidity 
Scores between non-frail and frail participants. This is in accordance with Fried et al’s 
conclusion that comorbidity, though a risk factor, is not synonymous with frailty [14]. 
Disability is a consequence of frailty, it is therefore unsurprising that within this cohort frail 
participants had a significantly worse performance status [14]. 
 
Studies have demonstrated a correlation between proinflammatory cytokines and white 
blood cell count with frailty in older adults [40-43]. Pro-inflammatory markers were not 
measured directly in our study, though there was no significant difference in other markers 
of inflammation between the non-frail and frail groups. Furthermore, low vitamin D levels 
have been associated with frailty in the older adult population [42,44]. However, there was 
no significant difference in vitamin D level between non-frail and frail groups in this cohort 
of CKD patients. These findings may be explained by the pathogenesis of frailty in CKD being 
distinct from the general older population, with factors such as the accumulation of uraemic 
toxins, reduced appetite, metabolic acidosis and anabolic hormone dysregulation 
contributing more prominently [2,18]. 
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Walking speed, hand grip strength and the SPPB have all been proposed as frailty screening 
measures [17,24,25,45,46]. However, poor physical performance of the lower limbs, rather 
than upper limbs, is most predictive of outcomes in patients with CKD [47]. Roshanravan et 
al demonstrated that walking speed is associated with mortality in patients with CKD, unlike 
hand grip strength [47]. Within our study, walking speed was the superior frailty screening 
test with excellent equipoise between sensitivity/specificity and positive predicative 
value/negative predictive value. Though AUC values were attenuated when the physical 
measures were compared against a modified version of the Frailty Phenotype, they 
remained high with walking speed again having the best performance. Clegg et al 
demonstrated that, in the general older population, walking speed similarly performs well 
as a frailty screening measure [17]. 
 
Recognising that a frailty screening programme involving detailed physical assessments 
would be a time-demanding endeavour, several non-physical assessment frailty measures 
were studied, specifically the Clinical Frailty Scale, PRISMA-7, CKD FI and CKD FI-LAB. The 
Clinical Frailty Scale had the best performance of these measures in terms of identifying 
frailty. It also has the most extensive evidence base for predicting outcomes in patients with 
CKD [15,48-50]. Alfaadhel et al demonstrated that each point increase in the Clinical Frailty 
Scale score at dialysis initiation was associated with a mortality hazard ratio of 1.22 (95% CI: 
1.04 to 1.43) [49]. Pugh et al also showed an association with Clinical Frailty Scale scores and 
mortality in a group of CKD patients referred for pre-dialysis education (hazard ratio 1.35 
[95% CI: 1.16–1.57]) [50]. Finally, Iyasere et al demonstrated that higher Clinical Frailty Scale 
scores are associated with worse health-related quality of life in older patients receiving 
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assisted peritoneal dialysis and haemodialysis [48]. The inter-rater reliability of the Clinical 
Frailty Scale requires further assessment in this population, including that of non-clinician 
users. 
 
Though the FI correlates with the Frailty Phenotype in the older population, it has only been 
validated in a CKD cohort against a modified version of the Frailty Phenotype that 
substituted objective measurements for self-reported alternatives [37,51]. The suggested 
cut-off of >0.21 considerably over-estimated the prevalence of frailty and offered poor 
specificity [26]. A cut-off of >0.32 provided a better balance between sensitivity and 
specificity. Physical assessment variables were deliberately not incorporated within the CKD 
FI. The rationale for doing so was to improve its practicality when used as a frailty screening 
method, though in its current form, it is still a time-demanding measure. Further study is 
needed on the prognostic value of the FI in CKD populations and of the feasibility of 
incorporating such a screening method in nephrology outpatient services. The electronic FI, 
described by Clegg et al, may improve the usability of the FI in CKD populations [52]. 
However, the construct validity of the electronic FI in patients with advanced CKD requires 
assessment. The FI-LAB, that consists of standard laboratory test result variables and 
systolic and diastolic blood pressure, has been studied in the older population [23]. It has 
been shown to correlate with the standard FI and to be predictive of outcomes in the older 
population [23,53,54]. However, the CKD FI-LAB only weakly correlated with the Frailty 
Phenotype and had a non-significant AUC value in the overall cohort, suggesting that it was 
not a useful test. This is especially disappointing given the wealth of laboratory variables 
available for the typical nephrology patient.  
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The PRISMA-7 correlated moderately with the Frailty Phenotype, compared with the strong 
correlation for the Clinical Frailty Scale and the CKD FI. Using the suggested cut-off of ≥3, 
the PRISMA 7 over-estimated the prevalence of frailty, though afforded a reasonable 
balance between sensitivity and specificity. This short questionnaire could certainly be 
incorporated into clinical practice, though the Clinical Frailty Scale should be considered in 
the first instance given its superior diagnostic accuracy. 
 
Notwithstanding the practical usefulness of this study, there are recognised limitations. 
Although the study's sample size allows an accurate assessment of the screening tests' 
correlation with the Frailty Phenotype and their respective AUC values, thus providing a 
valuable measure of their diagnostic accuracy, the precision of the screening tests' 
sensitivity and specificity would benefit from being examined in a larger sample. 
Furthermore, our data was obtained from a single-centre, with a predominantly Caucasian 
population. The high proportion of Caucasian participants recruited to the study may also 
reflect a necessary exclusion criterion, i.e. patients who do not have sufficient 
understanding of the English language to complete study questionnaires [55]. Ethnicity 
appears to affect the expression of frailty with studies showing a higher prevalence of frailty 
in those of Black and Hispanic ethnicity, though it has been reported that frailty is similarly 
hazardous regardless of ethnicity in those with dialysis-dependent CKD [4,56,57]. Further 
investigation within more culturally diverse cohorts is needed to verify the present results in 
those cohorts and confirm the generalisability of our results. Finally, the frailty screening 
methods used in our study were only performed at one time point and therefore we cannot 
report their reliability. Other studies have reported the reliability of physical assessment 
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measures, though the reliability of the Clinical Frailty Scale and PRISMA-7 have not been 
assessed in an advanced CKD cohort to our knowledge [58-60]. 
 
CONCLUSIONS 
 
Frailty is highly prevalent in CKD with the prevalence increasing with worsening kidney 
function. Walking speed is a very useful frailty screening measure in patients with advanced 
CKD, as is the case in the general older population [17]. If it is not practical to perform a 
physical assessment, a non-physical assessment of frailty should be performed. The Clinical 
Frailty Scale was the most accurate non-physical assessment and currently has the strongest 
evidence base for prognostication in advanced CKD populations [48-50]. Further study is 
needed on the optimum management strategies for frail patients with CKD. Walking speed 
or a Clinical Frailty Scale assessment could be used to identify physically frail patients for 
randomised controlled trials of management strategies that aim to improve outcomes of 
this vulnerable patient group. 
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TABLES 
 
Table 1. The Frailty Phenotype Assessment. 
Frailty Criteria Measure 
Unintentional Weight Loss ≥10 pounds or ≥5% body weight over the preceding 12 months. 
Weakness Hand grip strength frailty criterion cut offs: 
Men 
BMI ≤24: ≤29 kg 
BMI 24.1-26:  ≤30 kg 
BMI 26.1-28: ≤30 kg 
BMI >28: ≤32 kg 
 
Women 
BMI ≤23: ≤17 kg 
BMI 23.1-26: ≤17.3 kg 
BMI 26.1-29: ≤18 kg 
BMI >29: ≤21 kg 
Self-perceived Exhaustion Participants asked two statements from the Center for Epidemiological Studies Depression 
Scale: 
1. I felt that everything I did was an effort. 
2. I could not get going. 
Participants then asked: 
‘How often did you feel this?’ and provided the following scale: 
0 = rarely or none of the time 
1 = some of the time 
2 = moderate amount of the time 
3 = most of the time 
Frailty criterion: answers ≥2 
Slowness Walking speed frailty criterion cut offs: 
Men  
Height ≤173 cm: ≥7 seconds (≤0.65 m/s) 
Height >173 cm: ≥6 seconds (≤0.76 m/s) 
 
Women  
Height ≤159 cm: ≥7 seconds (≤0.65 m/s) 
Height >159cm: ≥6 seconds (≤0.76 m/s) 
Low Physical Activity Modified version of the Minnesota Leisure Time Questionnaire used to assess energy 
expenditure per week. Frailty criterion: Men <383 Kcals/week, Women <270 Kcals/week. 
Frailty diagnosed if 3 or more frailty criteria present. Pre-frailty, or intermediate frailty, defined as the presence of 1 or 2 
frailty criteria. 
 
 
 
 
 
 
 
Frailty Screening in Chronic Kidney Disease 
 
 
  30 
Table 2. The PRISMA-7 Questionnaire Frailty Screening Tool. 
Question Answer 
1. Are you more than 85 years old? Yes/No 
2. Male? Yes/No 
3. In general, do you have any health problems that require you to limit your activities? Yes/No 
4. Do you need someone to help you on a regular basis? Yes/No 
5. In general, do you have any health problems that require you to stay at home? Yes/No 
6. In case of need, can you count on someone close to you? Yes/No 
7. Do you regularly use a cane, a walker or a wheelchair to move about? Yes/No 
Total Number of ‘Yes’ Answers:  
Frail: ≥ 3 ‘Yes’ Answers 
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Table 3. Baseline Demographics and Clinical Characteristics of Non-Frail and Frail 
Participants (Defined by The Frailty Phenotype) in CKD G4-5D. 
 Non-Frail (n=71) Frail (n=19) Adjusted P Value 
Age, years 68 (±13) 73 (±11) 1.00 
Female, % 30 (42) 15 (79) 0.10 
Body Mass Index, kg/m2 29 (±6) 28 (±6) 1.00 
Treatment Modality, % 
- Pre-Dialysis 
- Haemodialysis 
 
51 (72) 
20 (28) 
 
9 (47) 
10 (53) 
 
0.99 
 
Charlson Comorbidity Index 3 (2) 4 (4) 1.00 
Diabetes Mellitus, % 16 (23) 8 (42) 1.00 
Karnofsky Score 80 (20) 60 (20) <0.001 
Medications 8 (±3) 11 (±5) 0.08 
Current or ex-smoker, % 40 (56) 9 (47) 1.00 
MMSE Score ≤27, % (n=87) 13 (19) 5 (29) 1.00 
Fall within last 6 months, % 11 (15) 5 (26) 1.00 
SCREEN I ≤50, % 53 (75) 17 (89) 1.00 
Blood Pressure, mmHg 
- Systolic 
- Diastolic 
 
148 (±19) 
74 (±14) 
 
149 (±25) 
67 (±15) 
 
1.00 
0.92 
Laboratory Variables 
- Haemoglobin, g/L 
- White Cell Count, x 109/L 
- Neutrophil/Lymphocyte Ratio 
- Corrected Calcium, mmol/L 
- Phosphate, mmol/L 
- Alkaline Phosphatase, U/L 
- Albumin, g/L 
- Total Protein, g/L 
- CRP, mg/L (n=64) 
- Ferritin, µg/L (n=73) 
- PTH, pmol/L (n=81) 
- Vitamin D, nmol/L (n=48) 
 
117.6 (±12.7) 
7.6 (±2.5) 
3.1 (2.0) 
2.3 (±0.1) 
1.4 (0.4) 
86.0 (38.0) 
41.3 (±3.3) 
67.7 (±5.3) 
5.0 (10.7) 
385.0 (594.3) 
19.8 (23.3) 
58.0 (35.5) 
 
111.4 (±14.6) 
8.0 (±2.6) 
3.3 (1.5) 
2.3 (±0.1) 
1.5 (0.6) 
92.0 (53.0) 
39.6 (±3.3) 
66.2 (±6.6) 
5.5 (8.4) 
503.0 (533.0) 
26.2 (25.0) 
55.0 (60.0) 
 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
MMSE, Mini-Mental State Examination. Data presented as number (%), mean (± SD) or 
median (IQR). 
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Table 4. Diagnostic Accuracy of Frailty Screening Methods (Using the Frailty Phenotype as Reference Standard) in CKD G4-5D. 
 
AUC, Area Under the Curve; CI, Confidence Interval; PPV, Positive Predictive Value; NPV, Negative Predictive Value; LR+, Positive Likelihood 
Ratio; LR-, Negative Likelihood Ratio. *Six participants did not have the pre-requisite number of variables to complete the CKD FI-LAB. 
 
 
 
 
 
 
Correlation Coefficient 
(95% CI) 
P Value AUC 
(95%CI) 
P Value Cut-off Frailty Prevalence 
(%) 
Sensitivity (95%CI) Specificity (95%CI) PPV 
(95%CI) 
NPV 
(95%CI) 
LR+ 
(95%CI) 
LR- 
(95%CI) 
Clinical Frailty Scale 0.77 (0.66 to 0.85) <0.001 0.90 (0.84 to 0.97) <0.001 ≥5 
≥4 
24 (27) 
51 (57) 
0.79 (0.57 to 0.91) 
1.00 (0.83 to 1.00) 
0.87 (0.78 to 0.93) 
0.55 (0.43 to 0.66) 
0.63 (0.43 to 0.79) 
0.37 (0.25 to 0.51) 
0.94 (0.85 to 0.98) 
1.00 (0.91 to 1.00) 
6.23 (3.28 to 12.00) 
2.22 (1.64 to 2.88) 
0.24 (0.10 to 0.50) 
0.00 (0.00 to 0.31) 
PRISMA-7 0.64 (0.50 to 0.75) <0.001 0.83 (0.73 to 0.93) <0.001 ≥3 45 (50) 0.89 (0.69 to 0.97)  0.61 (0.49 to 0.71) 0.38 (0.25 to 0.52) 0.96 (0.85 to 0.99) 2.27 (1.59 to 3.17) 0.17 (0.05 to 0.53) 
CKD FI 0.75 (0.65 to 0.81) <0.001 0.88 (0.81 to 0.96) <0.001 >0.21 
>0.32 
64 (71) 
41 (46) 
1.00 (0.83 to 1.00) 
0.95 (0.75 to 0.99) 
0.37 (0.26 to 0.48) 
0.68 (0.56 to 0.77) 
0.30 (0.20 to 0.42) 
0.44 (0.30 to 0.59) 
1.00 (0.87 to 1.00) 
0.98 (0.89 to 1.00) 
1.58 (1.22 to 1.89) 
2.92 (2.05 to 4.22) 
0.00 (0.00 to 0.47) 
0.08 (0.01 to 0.37) 
CKD FI-LAB* 0.26 (0.05 to 0.46) 0.02 0.63 (0.50-0.77) 0.08 - - - - - - - - 
Walking Speed 0.70 (0.55 to 0.80) <0.001 0.97 (0.93 to 1.00) <0.001 Frailty Phenotype Criterion 
≤0.8 m/s, or unable 
19 (21) 
28 (31) 
0.84 (0.62 to 0.94) 
0.95 (0.75 to 0.99) 
0.96 (0.88 to 0.99) 
0.86 (0.76 to 0.92) 
0.84 (0.62 to 0.94) 
0.64 (0.46 to 0.79) 
0.96 (0.88 to 0.99) 
0.98 (0.91 to 1.00) 
19.93 (7.02 to 58.95) 
6.72 (3.87 to 12.18) 
0.16 (0.06 to 0.39) 
0.06 (0.01 to 0.29) 
Hand Grip Strength -0.62 (-0.73 to -0.48) <0.001 0.87 (0.78 to 0.96) <0.001 Frailty Phenotype Criterion 
Men <30kg; Women <20kg 
43 (48) 
46 (51) 
1.00 (0.83 to 1.00) 
0.95 (0.75 to 0.99) 
0.66 (0.55 to 0.76) 
0.61 (0.49 to 0.71) 
0.44 (0.30 to 0.59) 
0.39 (0.26 to 0.54) 
1.00 (0.92 to 1.00) 
0.98 (0.88 to 1.00) 
2.96 (2.09 to 4.10) 
2.40 (1.74 to 3.31) 
0.00 (0.00 to 0.26) 
0.09 (0.02 to 0.41) 
SPPB -0.66 (-0.78 to -0.51)  <0.001 0.92 (0.86 to 0.97) <0.001 <10 
<9 
53 (59) 
35 (39) 
1.00 (0.83 to 1.00) 
1.00 (0.83 to 1.00) 
0.52 (0.41 to 0.63) 
0.77 (0.66 to 0.86) 
0.36 (0.24 to 0.49) 
0.54 (0.38 to 0.70) 
1.00 (0.91 to 1.00) 
1.00 (0.93 to 1.00) 
2.09 (1.56 to 2.67) 
4.44 (2.86 to 6.81) 
0.00 (0.00 to 0.33) 
0.00 (0.00 to 0.22) 
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Table 5. Diagnostic Accuracy of Frailty Screening Methods (Using the Frailty Phenotype as 
Reference Standard) in CKD G4-5D Categorised by Age and Dialysis-Dependency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUC, Area Under the Curve; CI, Confidence Interval. *Six participants did not have the pre-
requisite number of variables to complete the CKD FI-LAB. 
 
 
 
AUC Value (95% CI) P Value 
Clinical Frailty Scale 
- ≥65 years 
- <65 years 
- Pre-Dialysis 
- Dialysis-Dependent 
 
0.89 (0.80 to 0.98) 
0.93 (0.83 to 1.00) 
0.87 (0.76 to 0.98) 
0.93 (0.83 to 1.00) 
 
<0.001 
0.003 
0.001 
<0.001 
PRISMA-7  
- ≥65 years 
- <65 years 
- Pre-Dialysis 
- Dialysis-Dependent 
 
0.85 (0.76 to 0.94) 
0.76 (0.51 to 1.00) 
0.81 (0.66 to 0.95) 
0.86 (0.71 to 1.00) 
 
<0.001 
0.07 
0.004 
0.002 
CKD FI 
- ≥65 years 
- <65 years 
- Pre-Dialysis 
- Dialysis-Dependent 
 
0.89 (0.80 to 0.97) 
0.91 (0.80 to 1.00) 
0.86 (0.74 to 0.97) 
0.93 (0.84 to 1.00) 
 
<0.001 
0.01 
0.001 
<0.001 
CKD FI-LAB*  
- ≥65 years 
- <65 years 
- Pre-Dialysis 
- Dialysis-Dependent 
 
0.59 (0.43 to 0.75) 
0.83 (0.66 to 1.00) 
0.61 (0.42 to 0.81) 
0.58 (0.36 to 0.79) 
 
0.32 
0.02 
0.3 
0.51 
Walking Speed  
- ≥65 years 
- <65 years 
- Pre-Dialysis 
- Dialysis-Dependent 
 
0.96 (0.91 to 1.00) 
0.97 (0.91 to 1.00) 
0.98 (0.94 to 1.00) 
0.96 (0.90 to 1.00) 
 
<0.001 
0.001 
<0.001 
<0.001 
Hand Grip Strength  
- ≥65 years 
- <65 years 
- Pre-Dialysis 
- Dialysis-Dependent 
 
0.86 (0.76 to 0.97) 
0.88 (0.73 to 1.00) 
0.91 (0.81 to 1.00) 
0.78 (0.60 to 0.96) 
 
<0.001 
0.01 
<0.001 
0.02 
SPPB  
- ≥65 years 
- <65 years 
- Pre-Dialysis 
- Dialysis-Dependent 
 
0.90 (0.83 to 0.98) 
0.97 (0.92 to 1.00) 
0.91 (0.83 to 0.98) 
0.92 (0.83 to 1.00) 
 
<0.001 
0.001 
<0.001 
<0.001 
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FIGURE LEGENDS 
 
Figure 1. The Clinical Frailty Scale. 
The 9-point Clinical Frailty Scale was adapted from the 7-point scale used in the Canadian 
Study of Health and Aging and has been reprinted with permission of Geriatric Medicine 
Research, Dalhousie University, Halifax, Nova Scotia, Canada.  
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Figure 2. Participant Flow Diagram. 
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Figure 3. Prevalence of Robustness, Pre-Frailty and Frailty in CKD G4-5D Defined by the 
Frailty Phenotype. 
 
